| Document |
Document Title |
|
WO/2013/026726 |
The present invention provides compounds of formula I wherein Q is Q1 or Q2; A1, A2, A3 and A4 are independently of each other C-H, C-R7, or nitrogen; R1 is C1-C8haloalkyl; R2 is aryl or aryl substituted by one to five R11, or heteroaryl...
|
|
WO/2013/028307 |
This application relates to derivatives of hydrocarbon terpenes (e.g., myrcene or farnesene), to methods of making the derivatives, and to the use of the derivatives as oils, solvents, lubricants, additives or base oils for lubricant com...
|
|
WO/2013/026455 |
The present invention provides compounds comprising a substructure of below formula 3: or a salt or prodrug thereof and the use of such compounds in treatment of e.g. CNS disorders.
|
|
WO/2013/027774 |
The purpose of the present invention is, in the production of produce gamma-butyrolactone by the dehydrogenation reaction of 1,4-butanediol in the presence of a catalyst, to produce gamma-butyrolactone with high efficiency by preventing ...
|
|
WO/2013/027694 |
The purpose of the present invention is to provide a near infrared light-emitting compound which has an ability to highly specifically binding to Aβ, a high permeability through the blood-brain barrier, an ability to quickly disappear f...
|
|
WO/2013/026724 |
The present invention relates to compounds of formula (IA) wherein QA is QA1 or QA2 P is P1, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A1, A2, A3, A4, G1, Z, R1, R2, R3 and R4 are as defined in claim 1; or a ...
|
|
WO/2013/028289 |
Described herein are oxygen scavengers, oxygen scavenging polymeric compositions, and oxygen scavenging articles. The polymeric compositions comprising the oxygen scavengers may have utility in packaging, sealing, wrapping, and storing o...
|
|
WO/2013/025564 |
Furfural is produced from a xylan-containing lignocellulosic feedstock which is contacted with water in the presence of an acid catalyst. Specifically, the catalyst is sulfuric acid characterized by a room temperature pH in the range of ...
|
|
WO/2013/024730 |
This organic electroluminescent element, which uses a compound represented by the belowmentioned general formula, emits dark blue light and has a low change in chromaticity and a low change in driving voltage after long-term driving. (R1...
|
|
WO/2013/024162 |
This invention relates to an efficient procedure for purifying HMF by crystallization at low temperature from an organic solvent.
|
|
WO/2013/024898 |
The primary purpose of the present invention is to provide a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the present invention can include a heterocyclic compound represented by general formul...
|
|
WO/2013/025733 |
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one ...
|
|
WO/2013/024493 |
This invention relates to diterpenes of general formula (1) belonging to labdane class, isolated from Leucas stelligera, being useful for prevention, treatment, inhibition or controlling growth and proliferation of mycobacterial activity...
|
|
WO/2013/024493 |
This invention relates to diterpenes of general formula (1) belonging to labdane class, isolated from Leucas stelligera, being useful for prevention, treatment, inhibition or controlling growth and proliferation of mycobacterial activity...
|
|
WO/2013/026024 |
An energy curable bonding resin composition that prevents corrosion in metallic optical structures including DVDs includes at least one monomer, acrylated epoxidized soya bean oil, and a photoinitiator of among 2,4,6-trimethylbenzoyl-dip...
|
|
WO/2013/023140 |
Post purification processes and methods for making pure biobased gamma-butyrolactone from renewable carbon resources comprising filtration and/or distillation and/or peroxide treatment are described herein.
|
|
WO/2013/021971 |
[Problem] To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology reformation in a power generation layer, and whereby short-circuit current (Jsc) attenuation when emitting light is...
|
|
WO/2013/023140 |
Post purification processes and methods for making pure biobased gamma-butyrolactone from renewable carbon resources comprising filtration and/or distillation and/or peroxide treatment are described herein.
|
|
WO/2013/020285 |
Provided are a method for preparing Antrocin through total chemical synthesis and a use of a composition containing Antrocin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier in preparing drugs for s...
|
|
WO/2013/018105 |
A process for extracting vitamins and minerals from a first plant matter(s) is disclosed wherein the said first plant matter(s) is treated with acidic matter followed by extraction with water. Said treatment converts the water-insoluble ...
|
|
WO/2013/017654 |
Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R1 to R9 have meanings as defined in the Specification, are useful as estro...
|
|
WO/2013/016193 |
The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof...
|
|
WO/2013/014478 |
The invention relates to a novel process for preparation of dronedarone of formula (I) and pharmaceutically acceptable salts thereof : Formula (I) characterized in that a compound of formula (II) : Formula (II) is aminated with compound ...
|
|
WO/2013/014480 |
The invention relates to a novel process for preparation of dronedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that the compound of formula (II) is reduced, and the obtained product is isolated and,...
|
|
WO/2013/014479 |
The invention relates to a novel process for preparation of dronedarone of formula (I) and pharmaceutically acceptable salts thereof, characterized in that the compound of formula (II) is reacted with dibutylamine of formula (III), under...
|
|
WO/2013/014997 |
A novel metal salen complex compound having auto-magnetic properties, and a derivative thereof are provided. The present invention is a metal salen complex compound comprising any of the listed compounds.
|
|
WO/2013/014204 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/014204 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/016193 |
The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof...
|
|
WO/2013/012590 |
Methods for forming ammonium salts of C4 diacids in a fermentation process with removal of divalent metal carbonate salts are disclosed. The pH of fermentation broths for production of C4 diacids is controlled by adding alkaline oxygen c...
|
|
WO/2013/011893 |
Provided are: a novel (meth)acrylate compound which can yield a cured product having a high refractive index and is therefore suitable for optical materials; and a plastic lens obtained using the same. A compound which has a fluorene ske...
|
|
WO/2013/008700 |
An actinic ray-sensitive or radiation-sensitive resin composition, includes: (A) a compound represented by the following formula (I); and (B) a resin: wherein X represents an oxygen atom, a sulfur atom or -N(Rx)-; each of R1 to R8 and Rx...
|
|
WO/2013/007832 |
The present invention relates to a process for manufacturing tetrahydrofuran, tetrahydropyran and, more generally, cycloether derivatives through the cyclodehydration of 1,4- or 1,5- diols. More specifically, the process of the invention...
|
|
WO/2013/008044 |
The current invention covers the synthesis of (+) and (-) l-(5,5-diphenyItetrahydrofuran-3- yl)-N,N-dimethylmethanamine [(±)1] and [(-)1] respectively, including their pharmacologically acceptable acid addition salts. The new products c...
|
|
WO/2013/009844 |
C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds a...
|
|
WO/2013/009844 |
C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds a...
|
|
WO/2013/007586 |
The present invention relates to the production of compounds comprising nitrile functions and of cyclic imide compounds. It relates more particularly to the production of compounds comprising nitrile functions from compounds comprising c...
|
|
WO/2013/004190 |
Disclosed are immune-modulators of formula (I), the preparation method thereof, a pharmaceutical composition containing the immune-modulators, and the use of the pharmaceutical composition as a drug, especially as an immune-modulating dr...
|
|
WO/2013/005749 |
The present invention is a method for producing tetrahydrofuran by means of a cyclodehydration reaction of 1,4-butanediol in the presence of an acid catalyst having a pKa value of no greater than 4 in a reaction vessel, wherein a startin...
|
|
WO/2013/006539 |
A furfuryl alcohol derivative having the general formula X [-CH(OR)2]m is prepared by an aldehyde with a furfuryl alcohol in the presence of a copper catalyst. In this formula, X is an aliphatic, cycloaliphatic, aromatic or araliphatic g...
|
|
WO/2013/005750 |
The present invention is a method that is for producing tetrahydrofuran and that produces tetrahydrofuran by supplying a starting material 1,4-butanediol containing gamma-butyrolactone to a reaction tank and performing a cyclodehydration...
|
|
WO/2013/000395 |
Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof; the inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, imm...
|
|
WO/2013/002217 |
A compound which is represented by general formula (1) (wherein R1 to R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy, mercapto, nitro, or amino group, or an aromatic, alkoxy, aromatic-oxy, alkylamino, aromatic...
|
|
WO/2013/000275 |
Disclosed are compounds as shown as general formula (I), derivatives and uses thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c and X have the definition as same as the description.
|
|
WO/2013/002397 |
The present invention is a method for producing a furfural compound, comprising carrying out a dehydration reaction of a saccharide in an aqueous solution comprising the saccharide and water in the presence of magnesium sulfate.
|
|
WO/2013/003465 |
|
|
WO/2013/000846 |
The invention relates to a method for producing cyclic enol ethers of formulas (I) and/or (II).
|
|
WO/2013/001997 |
An organic light emitting element which realizes a high efficiency and long-life light emission is provided. An organic compound represented by the general formula [1] described in Claim 1 is provided. In the general formula [1], R1 to R...
|
|
WO/2012/175439 |
The invention provides a process for the preparation of valerolactone, said process comprising reacting levulinic acid with hydrogen by using a solid Ru catalyst, characterised in that the process is carried out in the presence of at lea...
|
|
WO/2012/175715 |
The invention relates to a compound of formula (I), where R1, R2, R7, m, n, and L1 are as defined in claim 1, and to the methods for preparing same, to the pharmaceutical compositions containing same, and to the uses thereof in the treat...
|
